Cargando…
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall surv...
Autores principales: | Hirooka, Yoshiki, Kasuya, Hideki, Ishikawa, Takuya, Kawashima, Hiroki, Ohno, Eizaburo, Villalobos, Itzel B., Naoe, Yoshinori, Ichinose, Toru, Koyama, Nobuto, Tanaka, Maki, Kodera, Yasuhiro, Goto, Hidemi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970460/ https://www.ncbi.nlm.nih.gov/pubmed/29801474 http://dx.doi.org/10.1186/s12885-018-4453-z |
Ejemplares similares
-
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
por: Eissa, Ibrahim Ragab, et al.
Publicado: (2017) -
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity
por: Hotta, Yoshihiro, et al.
Publicado: (2017) -
Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial
por: Hirooka, Yoshiki, et al.
Publicado: (2017) -
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
por: Abdelmoneim, Mohamed, et al.
Publicado: (2022) -
Feasibility of EUS-guided shear-wave measurement: A preliminary clinical study
por: Ohno, Eizaburo, et al.
Publicado: (2019)